No Love for Aducanumab From FDA Advisers

(MedPage Today) — An FDA advisory committee voted overwhelmingly against the data presented about the controversial Alzheimer’s drug candidate aducanumab Friday.
The agency’s Peripheral and Central Nervous System (PCNS) Drugs Advisory Committee…
Read More

Leave a Reply

%d bloggers like this: